GlassScriptPhysician profile
Ketan Desai
NPI 1689809535
$505.69
in general payments reported to CMS, 2019-2025
12 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.67 · 2021: $202 · 2023: $38.90 · 2024: $18.07 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $129.98 | 2021 | |
| Optinose US, INC. | $71.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.73 | 2025 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $52.62 | 2025 | |
| Glaxosmithkline, LLC. | $37.23 | 2023-2024 | Trelegy Ellipta |
| Corcept Therapeutics | $35.69 | 2025 | Korlym |
| Radius Health, INC. | $32.12 | 2025 | Tymlos |
| Ucb, INC. | $20.88 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $19.74 | 2023 | Dupixent |
| Ascendis Pharma Endocrinology INC | $16.99 | 2025 | Yorvipath |
| Alk-Abello, INC | $15.67 | 2020 | |
| Averitas Pharma INC. | $14.52 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ketan Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.